Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56

Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56

2 weeks from now

Jan 8, 2025  · Travere Therapeutics (TVTX) closed the last trading session at $19.08, gaining 1.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term …

nasdaq.com

Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: …

2 weeks from now

Jan 8, 2025  · The average of price targets set by Wall Street analysts indicates a potential upside of 42.6% in Travere (TVTX). While the effectiveness of this highly sought-after metric is …

zacks.com

Wall Street Analysts Think Travere (TVTX) Could Surge 66.29%: …

2 weeks from now

Jan 17, 2024  · The consensus price target hints at a 66.3% upside potential for Travere (TVTX). While empirical research shows that this sought-after metric is hardly effective, an upward …

yahoo.com

Wall Street Analysts See A 26.27% Upside In Travere (TVTX): Can …

2 weeks from now

Oct 23, 2024  · The mean of analysts' price targets for Travere (TVTX) points to a 26.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong …

yahoo.com

Travere Therapeutics Stock: A Deep Dive Into Analyst ... - Nasdaq

2 weeks from now

Oct 21, 2024  · Breaking: Wall Street's Next Big Mover Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major …

nasdaq.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating Of ...

2 weeks from now

Dec 30, 2024  · Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Thursday, October 31st.The company reported ($0.70) EPS for …

marketbeat.com

Why Travere Therapeutics Stock Bolted Higher This Week

2 weeks from now

Feb 23, 2023  · Filspari could generate peak sales in excess of $1.4 billion in this setting, according to various Wall Street analysts. That's a huge commercial opportunity for a …

fool.com

Travere Therapeutics-Wall Street Analysts Believe Travere (TVTX) …

2 weeks from now

Travere Therapeutics (TVTX) closed the last trading session at $19.08, gaining 1.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets …

reportify.ai

Breaking Down Travere Therapeutics: 23 Analysts Share Their Views

2 weeks from now

Oct 16, 2024  · Breaking: Wall Street's Next Big Mover Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major …

nasdaq.com

Wall Street Analysts See A 26.27% Upside In Travere (TVTX

2 weeks from now

Oct 23, 2024  · Travere Therapeutics (TVTX) closed the last trading session at $17.97, gaining 23.4% over the past four weeks, but there could be plenty of upside left in the stock if short …

nasdaq.com

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected To

2 weeks from now

16 hours ago  · Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share …

marketbeat.com

Travere Therapeutics Inc Stock Forecast, Predictions & Price Target

2 weeks from now

On average, 7 Wall Street analysts forecast TVTX's revenue for 2026 to be $40,559,971,934, with the lowest TVTX revenue forecast at $28,676,324,046, and the highest TVTX revenue …

wallstreetzen.com

Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level

2 weeks from now

Nov 19, 2024  · Kidney Disease Stock Pulls Back. On Nov. 11, Travere stock hit a 52-week high at 20.33. That's nearly 300% above its 52-week low at 5.12, which was set on April 25.

investors.com

Wall Street Analysts Think Travere (TVTX) Could Surge 66.29

2 weeks from now

Jan 17, 2024  · Shares of Travere Therapeutics (TVTX) have gained 2.1% over the past four weeks to close the last trading session at $8.90, but there could still be a solid upside left in …

nasdaq.com

Travere (TVTX) Q3 Earnings: How Key Metrics Compare To Wall …

2 weeks from now

Oct 31, 2024  · Travere Therapeutics (TVTX) reported $62.9 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 69.5%. EPS of -$0.70 for …

nasdaq.com